Senti Biosciences, Inc. announced strategic plan to focus research and development efforts on lead oncology candidate SENTI-202 for the treatment CD33 and/or FLT3 expressing hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), to continue to advance SENTI-401 through preclinical studies to target colorectal cancer and other CEA-positive solid tumors, and to pursue strategic geographic partnerships for clinical development of SENTI-301A for liver cancer, of which there is high prevalence in Asian territories.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3228 USD | -5.09% | -8.03% | -51.09% |
May. 17 | Senti Biosciences, Inc. Announces Executive Changes | CI |
May. 09 | Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-51.09% | 15.05M | |
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202